Company Profile

Atox Bio is a privately held biotechnology company focused on the discovery and development of novel mechanism-based modulators of co-stimulatory signaling, useful as therapeutics for the treatment of infectious and autoimmune diseases mediated by an excessive Th1-cell response. Atox Bio is now developing products for the treatment of:

• Infectious diseases:
  Severe sepsis and septic shock, highly lethal and constituting a strong unmet medical need.
• Autoimmune diseases:
  Rheumatoid arthritis and multiple sclerosis, chronic diseases constituting a strong and as yet unsatisfied medical need. 

Founded on groundbreaking technology

Atox Bio Inc. was founded in 2003, based on a groundbreaking superantigen antagonist technology developed by Drs. Raymond Kaempfer and Gila Arad of the Hebrew University of Jerusalem, Israel. They co-founded the company together with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Atox Bio is registered in Delaware as a privately held US company. Its R&D activities are conducted by the wholly owned Israeli subsidiary, Atox Bio Ltd.

Atox Bio’s innovative technology is based on a profound understanding of how the immune system is manipulated by superantigen toxins. The technology has the unique ability to halt the toxicity cascade before the activation of Th1 cells takes place.

This new technology, deciphering a novel mechanism of action in the immune system, provides a novel and highly efficient approach to the treatment of infectious and autoimmune diseases mediated by excessive Th1-cell responses, through manipulation of novel co-stimulatory ligand interactions discovered by Atox Bio's scientists, which are used also by superantigens.

Research funding of over $6.5 million was provided by the US Army and the US Defense Advanced Research Projects Agency (DARPA).

Atox Bio is developing AB103 in collaboration with the Hebrew University of Jerusalem, Israel, under a current award of $5.8 million from the US National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Atox Bio holds the exclusive license for the Intellectual Property of this product and its technology.